News & Events
 
The Drugs Technical Advisory Board has examined the issue of suspension of manufacture and sale of Pioglitazone on 19th July 2013 & has recommended that the Suspension of the drug should be revoked and allowed to be marketed subject to certain conditions the manufacturers shall mention on their package insert and promotional literature of the drug. Based on DTAB report Ministry of health & family welfare & Central Government revokes the notification G.S.R.379(E) dated 18th June 2013.
-------------------------------
A new study presented at EULAR 2013,the Annual Congress of the European League Against Rheumatism shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over the counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint Possible serious ADEs include gastrointestinal bleeding, peptic ulceration, high blood pressureand worsening heart failure.
-------------------------------
Researchers reported at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, that the increase in sugar consumption has led to more diabetes and heart disease over the past decade.
-------------------------------
People taking statin drugs to lower their cholesterol may slightly increase their risk for muscle and joint diseases as well as strains and sprains, a new study suggests.The results were published online June 3 in the journal JAMA Internal Medicine.

Testimonials
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
 
     
 
Metformin Hydrochloride Sustained Release and Voglibose Tablet
 
  COMPOSITION:  
  VOLPOST ®M 0.2mg : Metformin hydrochloride IP (as sustained release)500mg & Voglibose 0.2 mg.
VOLPOST ®M 0.3mg : Metformin hydrochloride IP (as sustained release)500mg & Voglibose 0.3 mg.
 
     
  THERAPEUTIC INDICATIONS:  
 
2nd line treatment for type II diabetes mellitus when diet, exercise, single agent do not result in adequate glycemic control.
 
     
  DOSAGE AND ADMINISTRATION:  
 
Adults - 1 tablet to be given 2-3 times daily with heavy meals. Safety and efficacy not established in children. Initiation at lower dose and close observation in case of elderly. Monitoring of renal function is necessary in elderly. Avoid in patients of hepatic insufficiency. Contraindicated in case of renal dysfunction.
 
     
  CONTRAINDICATIONS :  
 
Known hypersensitivity to metformin hydrochloride, voglibose or another component of this product renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥ 1.5mg/dL (males), ≥ 1.4 mg/dL (females) or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse, acute myocardial infarction and septicaemia; acute or chronic metabolic acidosis including diabetic ketoacidosis with or without coma.Volpost M should be temporarily discontinued in patients undergoing radiologic studies. Not to be used in patients with severe ketosis or in a state of diabetic coma or precoma, severe infections before or after operation or with severe trauma.
 
     
  WARNINGS:  
 
Lactic acidosis is a medical emergency that must be treated in hospital setting. Volpost M must be discontinued immediately and general supportive measures promptly instituted. For patients undergoing basic treatment for diabetes mellitus, voglibose should be given when 2-hr post prandial blood sugar is 200mg/dl or more. For patients on oral hypoglycemic drugs or insulin preparations, in addition to dietary treatment and/or exercise therapy, voglibose is to be given when the fasting blood sugar is about 140mg / dl or more. Closely monitor blood sugar at regular intervals.
 
     
  PRECAUTIONS:  
 
No clinical studies establishing conclusive evidence of macrovascular risk reduction with metformin or any other anti-diabetic drug. Before initiation of Volpost M therapy and annually while on Volpost M therapy renal function should be assessed and verified as being within normal range. Concomitant medication that may affect renal function or result in significant hemodynamic change or may interfere with disposition of metformin should be used with caution. Intravascular contrast studies with iodinated material can lead to acute alteration of renal function, hence metformin should be temporarily discontinued in whom such studies are planned. Drug should be promptly discontinued in case of cardiovascular collapse, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxemia (may be associated with lactic acidosis). Volpost M must be temporarily suspended before surgical intervention. Alcohol potentiates effect of metformin on lactate metabolism therefore patients should be warned against excessive alcohol intake. Volpost M is to be avoided in patients with clinical or laboratory evidence of hepatic disease. Measurement of serum vitamin B12 levels every two to three years is recommended. Patient with Type II diabetes, previously well controlled on metformin, who develops laboratory abnormality or clinical illness should be promptly evaluated for lactic acidosis or ketoacidosis. Hypoglycemia could occur when caloric intake is deficient or strenuous exercise is not compensated. Withhold Volpost M and temporarily administer insulin in case of temporary loss of glycemic control due to fever, trauma, infection or surgery. Periodic measurements of fasting blood glucose and glycosylated haemoglobin levels are required. Initial and periodic monitoring of hematologic parameters and renal function should be performed on annual basis. Administer carefully in patients receiving other antidiabetic drugs or with a history of laparotomy or ileus or with chronic intestinal disease accompanied by a disturbance in digestion and absorption or with Roemheld's syndrome, severe hernia or stenosis or ulceration of the large intestine or with serious hepatic dysfunction or with serious renal dysfunction.
 
     
  Back to Products  

 

 

         
 
 
Home | About Us | Products | Enquiry | Contact Us | Order | Carrer
     
  All Rights Reserved By : Cadell Health care Pvt Ltd. Designed & Maintained By : Daffodil Design & Prints